Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FORWARD II: Pegloticase Q4W vs Q2W with Methotrexate in Uncontrolled Refractory Gout
NCT06229145Phase 4Completed
- Sponsor
- Amgen
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of pegloticase in gout, sponsored by Amgen. Started Mar 2024; status: completed.
02
Drugs
pegloticase
03
Conditions
gout
Beyond the preview
Go deeper on NCT06229145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06229145.